Drugs / AQW051
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00409500 | Oct 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00418002 | May 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT00825539 | Jan 2009 → Nov 2011 | schizophrenia | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT01730768 | Sep 2012 → Dec 2013 | schizophrenia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01474421 | Sep 2011 → Feb 2013 | drug-induced dyskinesia, movement disorder | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01163227 | May 2010 → Sep 2011 | schizophrenia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00582855 | Dec 2007 → Feb 2009 | Alzheimer disease, amnestic disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AQW051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163227 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL3545232 ↗1“AQW051, an α7-nicotinic acetylcholine receptor partial agonist” PMID 27371157 ↗ Jun 2016 |
| Modality | Small molecule | — CHEMBL3545232 ↗ |
| Route | Oral | “individual oral doses of AQW051” NCT00409500 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL3545232 ↗ |